Holen Sie sich die Stockscreener-App
101.76
0.43%
0.44
Handel nachbörslich:
101.76
Schlusskurs vom Vortag:
$101.32
Offen:
$102.5
24-Stunden-Volumen:
1.59M
Relative Volume:
0.78
Marktkapitalisierung:
$19.87B
Einnahmen:
$4.58B
Nettoeinkommen (Verlust:
$870.87M
KGV:
23.13
EPS:
4.3988
Netto-Cashflow:
$945.58M
1W Leistung:
-3.46%
1M Leistung:
+18.09%
6M Leistung:
+55.83%
1J Leistung:
+43.22%
1-Tages-Spanne:
$101.08
$103.22
1-Wochen-Bereich:
$100.30
$107.31
52-Wochen-Spanne:
$53.56
$109.28
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Vergleichen Sie INCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
101.76 | 19.89B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.32 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.00 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.79 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.50 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.64 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Eingeleitet | Barclays | Overweight |
| 2025-06-16 | Hochstufung | Stifel | Hold → Buy |
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Is Incyte Corporation (ICY) stock among top earnings playsJuly 2025 Momentum & Fast Gain Swing Alerts - newser.com
Incyte to Present at Upcoming December 2025 Investor Conferences - BioSpace
Is Incyte Corporation (ICY) stock considered safe havenJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - newser.com
Incyte to Present at Upcoming Investor Conferences - Barchart.com
Incyte at Jefferies London: Strategic Shift to Diversification - Investing.com
Incyte Expands ‘Moments of Clarity’ With New Stories Spotlighting Chronic Skin Conditions - MyChesCo
Incyte Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
VP Denton Files To Sell 278 Of Incyte Corp [INCY] - TradingView
Is Incyte Corporation building a consolidation baseEarnings Recap Report & Verified Chart Pattern Signals - newser.com
Incyte (INCY) Receives Positive Opinion for Minjuvi in Europe - GuruFocus
Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL) - BioSpace
(tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL) - Business Wire
Can Incyte Corporation (ICY) stock attract analyst upgradesEarnings Trend Report & Reliable Entry Point Trade Alerts - newser.com
Forecasting Incyte Corporation price range with options dataJuly 2025 Outlook & Fast Entry High Yield Tips - newser.com
STATE STREET CORP Reduces Stake in Incyte Corp: A Strategic Port - GuruFocus
What risks investors should watch in Incyte Corporation stockTreasury Yields & AI Powered Market Entry Ideas - newser.com
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte Corp. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
Key metrics from Incyte Corporation’s quarterly dataJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Why Analysts See Incyte’s Story Shifting as Pipeline Progress Drives New Valuation Targets - Yahoo Finance
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Incyte Corporation stock see PE expansionQuarterly Growth Report & Weekly High Return Opportunities - newser.com
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte Prepares to Showcase Pipeline Momentum With New mutCALR Data at ASH 2025 - MyChesCo
Incyte (INCY): Exploring Valuation After Recent Share Price Rally and Pipeline Progress - Yahoo Finance
Incyte stock hits 52-week high at 108.81 USD By Investing.com - Investing.com Canada
Incyte stock hits 52-week high at 108.81 USD - Investing.com
Peering Into Incyte Corp's Recent Short Interest - Benzinga
Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains - 富途牛牛
Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus - MyChesCo
Prelude Strikes $910 Million Deal With Incyte for Groundbreaking JAK2 Cancer Therapy - MyChesCo
Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack - Yahoo Finance
Incyte at Guggenheim Conference: Strategic Focus on Innovation - Investing.com
Can Incyte Corporation stock hit record highs again2025 Performance Recap & Real-Time Volume Analysis - newser.com
Published on: 2025-11-10 05:29:16 - newser.com
Can Incyte Corporation stock deliver sustainable ROEMarket Growth Report & Reliable Price Action Trade Plans - newser.com
Incyte Posts 20% Revenue Growth, Raises 2025 Outlook on Strong Drug Demand - MyChesCo
Incyte and Enable Injections Join Forces to Advance At-Home Cancer Treatments - MyChesCo
Incyte to Highlight Innovation at Major Global Healthcare Conferences in November - MyChesCo
Prelude Therapeutics (PRLD): Valuation Snapshot Following Incyte Deal and Pipeline Realignment - Yahoo Finance
Will Incyte Corporation stock outperform Dow Jones indexBull Run & Weekly High Momentum Picks - newser.com
How Incyte Corporation stock responds to policy changesWeekly Trend Report & Smart Money Movement Alerts - newser.com
Incyte boosts annual sales forecast of blood cancer drug after strong quarter - MSN
[Form 4] INCYTE CORP Insider Trading Activity - Stock Titan
Incyte EVP Denton sells $60,613 in stock By Investing.com - Investing.com South Africa
Incyte EVP Denton sells $60,613 in stock - Investing.com India
Will Incyte Corporation (ICY) stock return to pre crash levels2025 Earnings Surprises & Real-Time Volume Trigger Notifications - newser.com
Is It Time to Reevaluate Incyte After Strong Pipeline Update and 52% Price Surge? - Yahoo Finance
Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema - The Joplin Globe
Leading vs lagging indicators on Incyte Corporation performanceJuly 2025 Summary & Real-Time Volume Triggers - newser.com
Incyte (INCY): Buy, Sell, or Hold Post Q3 Earnings? - Barchart.com
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):